Table 5 Univariable and multivariable analysis of factors associated with response to etanercept for extended and persistant oligoarticular JIA
Baseline characteristics | Poor vs Intermediate and Excellent Responders | Excellent vs Intermediate and Poor Responders | ||||||
|---|---|---|---|---|---|---|---|---|
Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
Extended oligoarticular JIA | ||||||||
Demographic | ||||||||
Disease duration before start of etanercept | 0.449 (0.146-1.144) | 0.114 | 1.066 (0.184-7.261) | 0.942 | 1.729 (0.723-4.87) | 0.245 | 6.808 (1.520-63.332) | 0.036 |
Age of disease onset | 0.561 (0.195-1.363) | 0.213 | 2.091 (0.788-9.563) | 0.218 | 3.447 (1.106-15.630) | 0.053 | ||
Disease activity | ||||||||
VAS disease activity by physician at start of etanercept | 0.361 (0.1-0.98) | 0.07 | 0.841 (0.173-3.997) | 0.816 | 1.271 (0.543-3.149) | 0.582 | ||
Pain joint count | 0.838 (0.333-2.186) | 0.695 | 0.668 (0.242-1.577) | 0.373 | 0.340 (0.070-1.097) | 0.104 | ||
Previous therapy | ||||||||
No. of DMARDs used before start of etanercept | 0.533 (0.19-1.343) | 0.198 | 0.518 (0.087-2.841) | 0.431 | 1.064 (0.449-2.613) | 0.885 | ||
Fact of biologics using before start of etanercept | 0.497 (0.188-1.193) | 0.123 | 0.440 (0.138-1.337) | 0.136 | 1.794 (0.729-6.57) | 0.253 | ||
Persistant oligoarticular JIA | ||||||||
Demographic | ||||||||
Disease duration before start of etanercept | 0.671 (0.385-1.216) | 0.157 | 1.118 (0.522-2.736) | 0.785 | 1.154 (0.731-1.807) | 0.527 | ||
Disease activity | ||||||||
Morning stiffness, min | 0.746 (0.429-1.391) | 0.302 | 1.386 (0.886-2.25) | 0.16 | 1.448 (0.902-2.413) | 0.129 | ||
Previous therapy | ||||||||
Oral corticosteroids before start of etanercept | 0.681 (0.389-1.095) | 0.093 | 0.927 (0.482-5.718) | 0.858 | 0.768 (0.149-1.297) | 0.487 | ||
No. of DMARDs used before start of etanercept | 0.633 (0.343-1.171) | 0.131 | 0.562 (0.250-1.232) | 0.145 | 1.629 (1.025-2.748) | 0.049 | 1.691 (1.04-2.958) | 0.046 |
Background therapy | ||||||||
Concomitant NSAID at start of etanercept | 0.838 (0.408-1.637) | 0.609 | 0.711 (0.445-1.12) | 0.145 | 0.649 (0.388-1.058) | 0.089 | ||
Laboratory tests | ||||||||
CRP at start of etanercept | 0.869 (0.515-1.791) | 0.635 | 1.3 (0.833-2.099) | 0.247 | 1.385 (0.874:2.274) | 0.164 | ||